Literature DB >> 16169340

Unsuccessful reperfusion in patients with ST-segment elevation myocardial infarction treated by primary angioplasty.

Giuseppe De Luca1, Arnoud W J van 't Hof, Jan Paul Ottervanger, Jan C A Hoorntje, A T Marcel Gosselink, Jan-Henk E Dambrink, Felix Zijlstra, Menko-Jan de Boer, Harry Suryapranata.   

Abstract

BACKGROUND: Several studies have shown that patency of the epicardial vessel does not guarantee optimal myocardial perfusion in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI). The aim of the current study was to identify clinical and angiographic correlates of unsuccessful reperfusion by the use of myocardial blush grade in a large consecutive cohort of STEMI patients.
METHODS: Our population is represented by a total of 1,548 consecutive patients with STEMI treated by primary angioplasty at our institution. All clinical and angiographic data were prospectively collected. Successful reperfusion was defined as postprocedural thrombolysis in myocardial infarction (TIMI) 3 flow with myocardial blush grades 2 to 3.
RESULTS: Poor myocardial reperfusion was observed in 358 patients (23.1%) and was associated with a significantly larger infarct size (1838 [350-3387] vs 1187 [607-2257], P < .0001) and lower ejection fraction (41 [31-48.2] vs 65 [36.5-52.5] P < .0001). At multivariate analysis, preprocedural TIMI flow 0 to 1, anterior infarction, ischemic time, postprocedural residual stenosis, advanced Killip class at presentation, and age were identified as independent predictors of poor myocardial reperfusion. At 1-year follow-up, a total of 92 patients (5.9%) had died. At multivariate analysis, including clinical and angiographic variables, unsuccessful reperfusion was an independent predictor of 1-year mortality (relative risk 3.11, 95% CI 1.99-4.87, P < .0001).
CONCLUSIONS: The prevalence of poor myocardial reperfusion is relatively high in patients undergoing primary angioplasty for STEMI, with a significant impact on 1-year mortality. Preprocedural TIMI flow, anterior infarction, ischemic time, Killip class at presentation, and age were independently associated with unsuccessful reperfusion. Future research should be focused on these high-risk patients, and treatment strategies should be developed to improve myocardial perfusion and clinical outcome.

Entities:  

Mesh:

Year:  2005        PMID: 16169340     DOI: 10.1016/j.ahj.2004.10.044

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

Review 1.  Thrombectomy during primary angioplasty: methods, devices, and clinical trial data.

Authors:  Giuseppe De Luca; Monica Verdoia; Ettore Cassetti
Journal:  Curr Cardiol Rep       Date:  2010-09       Impact factor: 2.931

2.  Aspiration thrombectomy and primary percutaneous coronary intervention.

Authors:  G De Luca; H Suryapranata; M Chiariello
Journal:  Heart       Date:  2006-05-02       Impact factor: 5.994

3.  Differential effects of post-dilation after stent deployment in patients presenting with and without acute myocardial infarction.

Authors:  Zhi-Jiang Zhang; Oscar C Marroquin; Roslyn A Stone; Joel L Weissfeld; Suresh R Mulukutla; Faith Selzer; Kevin E Kip
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

4.  Impact of vessel size on distal embolization, myocardial perfusion and clinical outcome in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction.

Authors:  Giuseppe De Luca; Harry Suryapranata; Menko-Jan de Boer; Jan Paul Ottervanger; Jan C A Hoorntje; A T Marcel Gosselink; Jan-Henk E Dambrink; Arnoud W J van't Hof
Journal:  J Thromb Thrombolysis       Date:  2007-12-21       Impact factor: 2.300

Review 5.  Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.

Authors:  Giuseppe De Luca; Stefano Savonitto; Arnoud W J van't Hof; Harry Suryapranata
Journal:  Drugs       Date:  2015-07       Impact factor: 9.546

6.  Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.

Authors:  Giuseppe De Luca; Arnoud W J van't Hof; Kurt Huber; C Michael Gibson; Francesco Bellandi; Hans-Richard Arntz; Mauro Maioli; Marko Noc; Simona Zorman; Gioel Gabrio Secco; Uwe Zeymer; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Tomasz Rakowski; Maryann Gyongyosi; Dariusz Dudek
Journal:  Heart Vessels       Date:  2013-03-14       Impact factor: 2.037

7.  Safety and efficacy of thrombectomy in patients undergoing primary percutaneous coronary intervention for acute ST elevation MI: a meta-analysis of randomized controlled trials.

Authors:  Umesh U Tamhane; Stanley Chetcuti; Irfan Hameed; P Michael Grossman; Mauro Moscucci; Hitinder S Gurm
Journal:  BMC Cardiovasc Disord       Date:  2010-02-26       Impact factor: 2.298

8.  Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

Authors:  Giuseppe De Luca; C Michael Gibson; Francesco Bellandi; Marko Noc; Mauro Maioli; Simona Zorman; Uwe Zeymer; H Mesquita Gabriel; Ayse Emre; Donald Cutlip; Hans-Richard Arntz; Dariusz Dudek; Tomasz Rakowski; Maryann Gyongyosi; Kurt Huber; Arnoud W J van't Hof
Journal:  J Thromb Thrombolysis       Date:  2010-07       Impact factor: 2.300

Review 9.  Risk profile and benefits from Gp IIb-IIIa inhibitors among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-regression analysis of randomized trials.

Authors:  Giuseppe De Luca; Eliano Navarese; Paolo Marino
Journal:  Eur Heart J       Date:  2009-10-28       Impact factor: 29.983

10.  Comparison of two visual angiographic perfusion grades in acute myocardial infarction.

Authors:  Tamás Ungi; Viktor Sasi; Imre Ungi; Tamás Forster; András Palkó; Attila Nemes
Journal:  Ups J Med Sci       Date:  2009       Impact factor: 2.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.